Drug Type ASO |
Synonyms SNP 614, SNP-614, SNP614 |
Target |
Action inhibitors |
Mechanism LRRK2 inhibitors(Leucine-rich repeat serine/threonine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Preclinical | China | 05 Dec 2022 |